Mylam, Karen Juul4; Nielsen, Anne Lerberg4; Pedersen, Lars Møller1; Hutchings, Martin2
1 Department of Anaesthesiology, Amager and Hvidovre Hospital, The Capital Region of Denmark2 Onkologisk Klinik, Finsencentret, Rigshospitalet, The Capital Region of Denmark3 Hæmatologisk Klinik, Finsencentret, Rigshospitalet, The Capital Region of Denmark4 unknown
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and potentially curable type of lymphoma. Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) is part of clinical routine for DLBCL in most hospitals and also recommended for staging and end-of-therapy evaluation. FDG-PET/computed tomography (CT) is able to identify nodal and extranodal sites with greater accuracy than CT alone. Little evidence supports the use of surveillance FDG-PET imaging in the follow-up setting because of high rates of false-positive scans and because most studies are retrospective. This article discusses FDG-PET assessment methods and the clinical application of FDG-PET for management of DLBCL.